IDYA (IDEAYA Biosciences) Moat Score: 4/10 (As of Jul. 05, 2026)


IDYA IDEAYA Biosciences Inc IDYA
54 GF Score
Price $37.66
GF Value $205.30
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IDEAYA Biosciences Moat Score?

IDEAYA Biosciences IDYA +4.12% 54 Moat Score is 4 as of Jul. 05, 2026. GuruFocus rates IDYA with a GF Score™ of 54/100 and a GF Value™ of $205.30 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,395 Biotechnology companies, IDEAYA Biosciences ranks better than 88.75% on this metric.

IDEAYA Biosciences has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

IDEAYA Biosciences has Narrow Moat: IDEAYA Biosciences Inc has a discernible but modest moat due to its valuable patents and R&D capabilities. However, it lacks strong market leadership and faces significant competition in the biotech sector.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes IDEAYA Biosciences might have Narrow Moat - Discernible but modest moat.

IDEAYA Biosciences  (NAS:IDYA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

IDEAYA Biosciences Moat Score Related Terms

IDYA vs PBLS, ELVN, BEAM: Moat Score Comparison

For the Biotechnology subindustry, IDEAYA Biosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDEAYA Biosciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where IDEAYA Biosciences's Moat Score falls into.


IDYA
54GF Score
IDEAYA Biosciences Inc IDYA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
IDEAYA Biosciences (IDYA) has a Moat Score of 4 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, IDEAYA Biosciences ranks #157 out of 1395 companies in the Biotechnology industry, placing it in the top 11.3%.
Is IDEAYA Biosciences' Moat Score too high?
IDEAYA Biosciences' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. IDEAYA Biosciences' value of 4 is 100% above this industry median. Based on the distribution chart, IDEAYA Biosciences ranks #157 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, IDEAYA Biosciences has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IDEAYA Biosciences' Moat Score compare to PBLS and ELVN?
According to the Biotechnology industry distribution chart, IDEAYA Biosciences ranks #157 out of 1395 companies for Moat Score. This places IDEAYA Biosciences in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. IDEAYA Biosciences' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEAYA Biosciences's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEAYA Biosciences's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEAYA Biosciences stock overvalued right now?
Based on GuruFocus' analysis, IDEAYA Biosciences (IDYA) is currently considered Possible Value Trap. The stock's GF Value™ is $205.30, compared to a current price of $37.66 — trading 81.7% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. IDEAYA Biosciences' overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For IDEAYA Biosciences (IDYA), the current Moat Score is 4 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEAYA Biosciences (IDYA) Overvalued in 2026?

Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued. The current stock price of $37.66 is trading 81.7% below its estimated GF Value™ of $205.30. GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.

Key valuation signals for IDYA:

  • Moat Score: 4
  • GF Value™: $205.30 vs. price of $37.66 (81.7% below fair value)
  • GF Score™: 54/100 with 6 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1395)

No single metric tells the full story. See the IDYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDEAYA Biosciences Business Description

Other Exchanges 30J:Germany
Address 5000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
54GF Score

Get the complete analysis for IDYA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.66
Price
$205.30
GF Value